Life Science News
Latest updates from the biotech and pharma world
FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Novartis was the sole bidder in $12B deal to buy Avidity
#Avidity Biosciences#buy Avidity#chief executives#billion agreement#sole bidder
FDA's Pazdur is said to raise questions about commissioners actions, new voucher
#commissioners actions#raise questions#FDA Pazdur#Richard Pazdur#Marty Makary
UK-US drug pricing deal could come as early as this week, sources say
#told Endpoints#UK-US drug#matter told#drug pricing#pricing deal
#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins
#American Society#wins Late-breaking#Big pharma#Novartis spell#Late-breaking abstracts
J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study
#fails Phase#Alzheimer study#study Johnson#early-stage disease#promising candidates
Kelun's TROP2 ADC plus Keytruda improves outcomes in first-line lung cancer
#first-line lung#lung cancer#cancer Merck#Keytruda improves#Chinese regulatory
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis data
#Clearside Biomedical#MindImmune Therapeutics#Enlivex reports#pay Arrowhead#continues type
Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeutics
#Versant Ventures’#Dayra Therapeutics#Ventures’ latest#Therapeutics Versant#Versant macrocycle
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win
#win Bayer#high-profile failures#stock rallies#next-gen blood#blood thinner
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
#Novo Nordisk#closely-watched Alzheimer#long shot#long shots#Nordisk semaglutide
Craig Crews, Mikael Dolsten raise $32M for Quarry Thera
#Mikael Dolsten#Quarry Thera#Craig Crews#Dolsten raise#Mikael
Nobel laureate Carolyn Bertozzi to rejoin Lilly board
#Carolyn Bertozzi#Eli Lilly#SEC filing#Friday evening#evening SEC
Makary’s user fee comments; M&A activity stays hot; A new use for prime editing; and more
#Endpoints Weekly#fee comments#stays hot#prime editing#user fee
Top Makary aide Jain-Nagpal remains at the FDA after White House pushback
#White House#Commissioner Marty#FDA Commissioner#Marty Makary#Top Makary
AstraZeneca to onshore rare disease portfolio as part of its $50B pledge to the US
#announced Friday#billion pledge#onshore rare#rare disease#disease portfolio
Teva loses IRA drug pricing challenge in DC federal court
#federal court#loses IRA#IRA drug#Medicare negotiations#pharma industry
Sarepta ends Elevidys trial with Hansa's pre-treatment; Some pipeline cuts at Moderna
#Blue Lake#Inhibikase Therapeutics#Olema Oncology#Elevidys trial#Hansa Biopharma